SCHEMBL20176868

SCHEMBL20176868

Cc1ccc(Oc2cccnc2)nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TDP1 Q9NUW8 1/20 0.50
LTA4H P09960 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 2/20 0.44
SYK P43405 1/20 0.44
MAP4K4 O95819 1/20 0.43
GRM5 P41594 2/20 0.43
CYP19A1 P11511 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
GALR3 O60755 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL753331 0.80 BCAT2 (0.60) LMNALTA4HKMT2AMEN1ALDH1A1
SCHEMBL20176871 0.78 MEN1 (0.55) LMNALTA4HKMT2AMEN1ALDH1A1
SCHEMBL29972517 0.77 LMNA (0.60) LMNATDP1LTA4HALDH1A1GRM5
SCHEMBL20176876 0.77 LMNA (0.60) LMNATDP1LTA4HALDH1A1GRM5
SCHEMBL8736798 0.76 LMNA (0.60) LMNATDP1LTA4HKMT2AALDH1A1
SCHEMBL20176878 0.76 LMNA (0.50) LMNATDP1LTA4HKMT2AALDH1A1
SCHEMBL8184955 0.75 LMNA (0.49) LMNATDP1LTA4HKMT2AALDH1A1
SCHEMBL676142 0.74 LMNA (0.82) LMNATDP1LTA4HALDH1A1MAP4K4
SCHEMBL30535283 0.74 LMNA (0.82) LMNATDP1LTA4HALDH1A1MAP4K4
SCHEMBL17623917 0.73 LMNA (0.51) LMNATDP1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190352276-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE JOINT STOCK COMPANY "BIOCAD" (RU) 2019-11-21 US disclosed
WO-2018092047-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE JOINT STOCK COMPANY "BIOCAD" (RU) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352276-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, ABL1, CNKSR1 LMNA 946/4885TDP1 1826/4885LTA4H 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.